Statistics
Publications
36.6K
Citations
7.6M
Authors
8K
Location
Rahway, United States
36.6K
8K
Merck & Co., Inc., Rahway, NJ, USA (United States), United States
286 publications · 38.1K citations
96
h-index
Merck & Co., Inc., Rahway, NJ, USA (United States), United States
213 publications · 31.5K citations
77
h-index
Merck & Co., Inc., Rahway, NJ, USA (United States), United States
554 publications · 23.5K citations
75
h-index
Merck & Co., Inc., Rahway, NJ, USA (United States), United States
302 publications · 17.4K citations
75
h-index
Merck & Co., Inc., Rahway, NJ, USA (United States), United States
190 publications · 48.3K citations
75
h-index
1–5 of 8K
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith et al. · Science · 2017 · 6.6K citations
Life Sciences, Immunology, Oncology +17
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley et al. · Nature · 2014 · 6.6K citations · Full text
Life Sciences, Immunology, Pathology +14
1–5 of 36.6K